
    
      OBJECTIVES: I. Evaluate the efficacy of ganglioside GD2-specific monoclonal antibody 3F8 as
      adjuvant therapy in patients with Stage IV neuroblastoma in second remission.

      OUTLINE: Biological Response Modifier Therapy. Antiganglioside GD2-specific Monoclonal
      Antibody 3F8, MOAB 3F8.

      PROJECTED ACCRUAL: A maximum of 20 patients will be entered.
    
  